Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy.
OBJECTIVE
To investigate long-term results of vitrectomy for the removal of submacular hard exudates in patients with diabetic maculopathy.


METHODS
Thirteen eyes of 10 patients with diabetic maculopathy underwent vitrectomy to remove submacular hard exudates from December 1993 to March 1999. The mean preoperative logMAR visual acuity +/- SD was 1.54 +/- 0.43. Preoperatively, the exudates ranged from 0.5 to 3 disk diameters (average, 1.25 disk diameters). Exudates were removed using subretinal forceps through a minimal paramacular retinotomy after vitrectomy. In all cases, 20% SF6 gas tamponade was added. The mean postoperative observation period was 43.2 months.


RESULTS
Visual acuity was improved in 7 eyes (54%) 1 year after surgery; however, visual acuity over longer periods was improved in only 5 eyes (38%) as compared with the preoperative findings. The mean final visual acuity +/- SD was 1.62 +/- 0.59, which did not show statistically significant improvement over that in the control group. Although submacular hard exudates and macular edema disappeared during the postoperative period, atrophic or degenerative changes occurred in many cases.


CONCLUSIONS
Visual improvement could not be obtained for a long period after removing submacular hard exudates in most of the patients, suggesting that diabetic maculopathy should be treated before massive exudate deposits appear in the macula.
Takaya
Kaori
K
Department of Ophthalmology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.
Suzuki
Yukihiko
Y
Mizutani
Hideyuki
H
Sakuraba
Tomoki
T
Nakazawa
Mitsuru
M
D000368:Aged; D003930:Diabetic Retinopathy / Q000150:complications / Q000601:surgery*; D005122:Exudates and Transudates; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007431:Intraoperative Complications; D008269:Macular Edema / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D013459:Sulfur Hexafluoride / Q000627:therapeutic use; D014792:Visual Acuity; D014821:Vitrectomy
D013459:Sulfur Hexafluoride